Display options
Cite
Terrin ML. Continuous intravenous epoprostenol improved survival, clinical status and hemodynamics in patients with severe primary pulmonary hypertension. Evid Based Cardiovasc Med. 1997;1(1):21doi: 10.1016/s1361-2611(97)80090-5.
Terrin, M. L. (1997). Continuous intravenous epoprostenol improved survival, clinical status and hemodynamics in patients with severe primary pulmonary hypertension. Evidence-based cardiovascular medicine, 1(1), 21. https://doi.org/10.1016/s1361-2611(97)80090-5
Terrin, M L. "Continuous intravenous epoprostenol improved survival, clinical status and hemodynamics in patients with severe primary pulmonary hypertension." Evidence-based cardiovascular medicine vol. 1,1 (1997): 21. doi: https://doi.org/10.1016/s1361-2611(97)80090-5
Terrin ML. Continuous intravenous epoprostenol improved survival, clinical status and hemodynamics in patients with severe primary pulmonary hypertension. Evid Based Cardiovasc Med. 1997 Apr;1(1):21. doi: 10.1016/s1361-2611(97)80090-5. PMID: 16379691.
Copy Download .nbib Format: NLM
Share it on

Evid Based Cardiovasc Med. 1997 Apr;1(1):21. doi: 10.1016/s1361-2611(97)80090-5.

Continuous intravenous epoprostenol improved survival, clinical status and hemodynamics in patients with severe primary pulmonary hypertension.

Evidence-based cardiovascular medicine

M L Terrin

Affiliations

  1. Maryland Medical Research Institute, Baltimore, USA.

PMID: 16379691 DOI: 10.1016/s1361-2611(97)80090-5

[No abstract available.]

Publication Types